Catalio Capital Management has closed its $400 million Nexus Fund IV to invest in novel healthcare innovations amid a challenging buyer’s market in biotech. The fund supports new company launches focusing on immunology and cancer genomics. Meanwhile, the genome and molecular diagnostics sector showed an average 6% stock price gain in June 2025, outpacing broader indices, with notable performers including Ginkgo Bioworks and Personalis, driven by positive clinical data and expansion in minimal residual disease testing. Concurrently, Apple Tree Partners is engaged in legal disputes with key investors, warning of portfolio company collapses, adding strain on biotech venture capital dynamics.